MARÍA PILAR
GARCÍA ALFONSO
Profesora asociada de Ciencias de la Salud
Publicaciones (149) Publicaciones de MARÍA PILAR GARCÍA ALFONSO
2024
-
Delphi consensus for the third-line treatment of metastatic colorectal cancer
Clinical and Translational Oncology
2023
-
A signature of circulating microRNAs predicts the response to treatment with FOLFIRI plus aflibercept in metastatic colorectal cancer patients
Biomedicine and Pharmacotherapy, Vol. 159
-
An international comparative analysis and roadmap to sustainable biosimilar markets
Frontiers in Pharmacology, Vol. 14
-
Association of Circulating Tumor Cells and Tumor Molecular Profile With Clinical Outcomes in Patients With Previously Untreated Metastatic Colorectal Cancer: A Pooled Analysis of the Phase III VISNÚ-1 and Phase II VISNÚ-2 Randomized Trials
Clinical Colorectal Cancer, Vol. 22, Núm. 2, pp. 222-230
-
Cost-effectiveness of apixaban and rivaroxaban in thromboprophylaxis of cancer patients treated with chemotherapy in Spain
Journal of Medical Economics, Vol. 26, Núm. 1, pp. 1145-1154
-
Expert consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology on the determination of biomarkers in pancreatic and biliary tract cancer
Revista Espanola de Patologia, Vol. 56, Núm. 1, pp. 32-44
-
Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): an international, multicentre, randomised, double-blind, phase 3 study
The Lancet, Vol. 402, Núm. 10395, pp. 41-53
-
Health-related quality of life (HRQoL) associated with fruquintinib in the global phase 3, placebo-controlled, double-blind FRESCO-2 study.
Journal of Clinical Oncology
-
Liquid Biopsy Detects Early Molecular Response and Predicts Benefit to First-Line Chemotherapy plus Cetuximab in Metastatic Colorectal Cancer: PLATFORM-B Study
Clinical cancer research : an official journal of the American Association for Cancer Research, Vol. 29, Núm. 2, pp. 379-388
-
Post-Chemoradiation Metastatic, Persistent and Resistant Nodes in Locally Advanced Rectal Cancer: Metrics and Their Impact on Long-Term Outcome
Cancers, Vol. 15, Núm. 18
-
Recommendations for the optimal management of peritoneal metastases in patients with colorectal cancer: a TTD and GECOP-SEOQ expert consensus statement
Clinical and Translational Oncology, Vol. 25, Núm. 12, pp. 3378-3394
-
SEOM-GEMCAD-TTD clinical guidelines for the systemic treatment of metastatic colorectal cancer (2022)
Clinical and Translational Oncology, Vol. 25, Núm. 9, pp. 2718-2731
2022
-
A randomised phase 2 study comparing different dose approaches of induction treatment of regorafenib in previously treated metastatic colorectal cancer patients (REARRANGE trial)
European Journal of Cancer, Vol. 177, pp. 154-163
-
Association of miR-21 and miR-335 to microsatellite instability and prognosis in stage III colorectal cancer
Cancer Biomarkers, Vol. 34, Núm. 2, pp. 201-210
-
Consensus of experts from the Spanish Pharmacogenetics and Pharmacogenomics Society and the Spanish Society of Medical Oncology for the genotyping of DPYD in cancer patients who are candidates for treatment with fluoropyrimidines
Clinical and Translational Oncology, Vol. 24, Núm. 3, pp. 483-494
-
Effect of aflibercept plus FOLFIRI and potential efficacy biomarkers in patients with metastatic colorectal cancer: the POLAF trial
British Journal of Cancer, Vol. 126, Núm. 6, pp. 874-880
-
Evolution of RAS Mutations in Cell-Free DNA of Patients with Tissue RAS Wild-Type Metastatic Colorectal Cancer Receiving First-Line Treatment: The PERSEIDA Study
Cancers, Vol. 14, Núm. 24
-
Expert consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology on the determination of biomarkers in pancreatic and biliary tract cancer
Clinical and Translational Oncology, Vol. 24, Núm. 11, pp. 2107-2119
-
First-Line Nivolumab Plus Low-Dose Ipilimumab for Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer: The Phase II CheckMate 142 Study
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 40, Núm. 2, pp. 161-170
-
First-line trifluridine/tipiracil + bevacizumab in patients with unresectable metastatic colorectal cancer: final survival analysis in the TASCO1 study
British Journal of Cancer, Vol. 126, Núm. 11, pp. 1548-1554